Community hub
Recent from talks
Contribute something
Nothing was collected or created yet.
Macimorelin
View on Wikipedia | |
| Clinical data | |
|---|---|
| Trade names | Macrilen |
| Other names | Aib-Trp-gTrp-CHO; AEZS-130; JMV 1843; Macimorelin acetate |
| AHFS/Drugs.com | Professional Drug Facts |
| License data |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Hepatic (CYP3A4-mediated) |
| Elimination half-life | 4.1 hours |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H30N6O3 |
| Molar mass | 474.565 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Macimorelin (INN) – or Macrilen (trade name) – is a drug that was developed by Aeterna Zentaris for use in the diagnosis of adult growth hormone deficiency.[3] Macimorelin acetate, the salt formulation, is a synthetic growth hormone secretagogue receptor agonist.[4] It is a growth hormone secretagogue receptor (ghrelin receptor) agonist, causing release of growth hormone from the pituitary gland.[5][6][7] Macimorelin acetate is described chemically as D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-acetate.
Macimorelin (Macrilen) was invented and first synthesized at University of Montpellier, Centre National de la Recherche Scientitifique (CNRS), France.[8][9][10] This transpired from a long-lasting research collaboration with Aeterna Zentaris. Aeterna Zentaris later in-licensed macimorelin as a development candidate from the CNRS and proceeded with the pre-clinical and clinical development of the compound.
As of January 2014, it was in Phase III clinical trials.[11] The phase III trial for growth hormone deficiency is expected to be complete in December 2016.[12]
As of December 2017, it was FDA-approved as a method to diagnose growth hormone deficiency.[13][14] Traditionally, growth hormone deficiency was diagnosed via means of insulin tolerance test (IST) or glucagon stimulation test (GST). These two means are done parenterally, whereas Macrilen boasts an oral formulation for ease of administration for patients and providers.
In November 2018 Novo Nordisk would acquire the rights to Macrilen, at a cost of $145 million.[15] In 2022 Novo Nordisk would give up their rights to Macrilen, returning them and all associated licensing to Aeterna Zentaris.[16]
The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[17]
See also
[edit]References
[edit]- ^ "Macimorelin Aeterna Zentaris". European Medicines Agency (EMA). 13 November 2018. Retrieved 28 September 2020.
- ^ "Ghryvelin (previously Macimorelin Aeterna Zentaris)". European Medicines Agency. 26 February 2019. Retrieved 15 May 2024.
- ^ "Macimorelin Aeterna Zentaris". www.ema.europa.eu. 13 November 2018.
- ^ "Macrilen Prescribing Information" (PDF). Retrieved 2018-07-25.
- ^ "Macimorelin". NCI Drug Dictionary. National Cancer Institute.
- ^ Koch L (June 2013). "Growth hormone in health and disease: Novel ghrelin mimetic is safe and effective as a GH stimulation test". Nature Reviews. Endocrinology. 9 (6): 315. doi:10.1038/nrendo.2013.89. PMID 23591367. S2CID 10475359.
- ^ Garcia JM, Swerdloff R, Wang C, Kyle M, Kipnes M, Biller BM, et al. (June 2013). "Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency". The Journal of Clinical Endocrinology and Metabolism. 98 (6): 2422–2429. doi:10.1210/jc.2013-1157. PMC 4207947. PMID 23559086.
- ^ WO 2001096300, Martinez J, Fehrentz JA, Guerlavais V, "Growth hormone secretagogues", published 20 December 2001, assigned to Zentaris AG
- ^ Broglio F, Boutignon F, Benso A, Gottero C, Prodam F, Arvat E, et al. (September 2002). "EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man". Journal of Endocrinological Investigation. 25 (8): RC26–RC28. doi:10.1007/BF03345096. PMID 12240910. S2CID 25962252.
- ^ Guerlavais V, Boeglin D, Mousseaux D, Oiry C, Heitz A, Deghenghi R, et al. (March 2003). "New active series of growth hormone secretagogues". Journal of Medicinal Chemistry. 46 (7): 1191–1203. doi:10.1021/jm020985q. PMID 12646029.
- ^ "Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA". The Wall Street Journal. January 6, 2014.
- ^ Clinical trial number NCT02558829 for "Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency" at ClinicalTrials.gov
- ^ "Drug Approvals and Databases - Drug Trials Snapshots: Marcrilen". www.fda.gov. Archived from the original on January 25, 2018. Retrieved 2018-07-25.
- ^ "FDA Approves Aeterna Zentaris' Macimorelin Growth Hormone Deficiency Test". HCPLive. 21 December 2017. Retrieved 2021-07-04.
- ^ "Novo Nordisk to buy rights to Strongbridge's Macrilen for $145m". Pharmaceutical Technology. 2018-11-01. Retrieved 2025-09-11.
- ^ "Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk". Aeterna Zentaris. 2022-08-29. Retrieved 2025-09-11.
- ^ New Drug Therapy Approvals 2017. U.S. Food and Drug Administration (FDA) (Report). January 2018. Archived from the original (PDF) on September 14, 2019. Retrieved 16 September 2020.
